Development asset linked to Ark Therapeutics in public FDA and regional records.
pharma · Hyperphagia · Bariatric Surgery · AARD
Ark Therapeutics
Ark Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boulder, USA HQ
2025 Founded
4 Employees
Public company Type
AARD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2025
- Employees
- 4
- Programs
- 6
- Drugs
- 5
- Patents
- 7
Ark Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ark Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Ark Therapeutics in public FDA and regional records.
-
Development asset linked to Ark Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement